Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib

NCT03710824 · clinicaltrials.gov ↗

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: Nintedanib

Sponsor

Boehringer Ingelheim